Non-publication of large randomized clinical trials: cross sectional analysis
Article Nov 01, 2013
Christopher W. Jones, Lara Handler, Karen E. Crowell, Lukas G. Keil, Mark A Weaver, Timothy F. Platts-Mills
BMJ (formerly British Medical Journal)
Objective: To estimate the frequency with which results of large randomized clinical trials registered with ClinicalTrials.gov are not available to the public.
Design: Cross sectional analysis.
Setting: Trials with at least 500 participants that were prospectively registered with ClinicalTrials.gov and completed prior to January 2009.
Data Sources: PubMed, Google Scholar, and Embase were searched to identify published manuscripts containing trial results. The final literature search occurred in November 2012. Registry entries for unpublished trials were reviewed to determine whether results for these studies were available in the ClinicalTrials.gov results database.
Main Outcome Measures: The frequency of non-publication of trial results and, among unpublished studies, the frequency with which results are unavailable in the ClinicalTrials.gov database.
Results: Of 585 registered trials, 171 (29%) remained unpublished. These 171 unpublished trials had an estimated total enrollment of 299?763 study participants. The median time between study completion and the final literature search was 60 months for unpublished trials. Non-publication was more common among trials that received industry funding (150/468, 32%) than those that did not (21/117, 18%), P=0.003. Of the 171 unpublished trials, 133 (78%) had no results available in ClinicalTrials.gov.
Conclusions: Among this group of large clinical trials, non-publication of results was common and the availability of results in the ClinicalTrials.gov database was limited. A substantial number of study participants were exposed to the risks of trial participation without the societal benefits that accompany the dissemination of trial results.
As many people spent the summer trying to keep the flies away from their fruit-bowls, an international group of scientists published one of the biggest and most important datasets in the field of connectomics to date, the complete 3D electron micrograph volume of the fruit-fly (Drosophila melanogaster) brain.READ MORE
What if immunotherapy was the solution to cure Alzheimer’s disease (AD)? AD represents a major health issue as it affects an increasing number of people each year. The search for a therapy against AD is uncertain. Nevertheless, we can hope that the fast-growing advances in biotechnologies could lead to an improvement in diagnostics and a better understanding of the disease.READ MORE